Efficiently transition to clinical trials
Minimizing the whitespace between phases is possible.
Find out how continuity principles can accelerate your drug development program with Eric Lang, MD.
Today, many licensing partners are pushing the acquisition milestone further into the development process...
... looking for clinical data that reinforce the viability of your molecule post IND/CTA approval. But how do you move from nonclinical to clinical without missing a beat? Review these tools to discover economic implementation solutions that can help your program seamlessly transition to its next development phase, enabling you to build the robust data set you need, expeditiously.